Janux Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.11.24	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies (Businesswire)
06.11.24	Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (Businesswire)
07.08.24	Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (Businesswire)
22.07.24	Janux Therapeutics Announces Updates to Board of Directors (Businesswire)
07.05.24	Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (Businesswire)
08.03.24	Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Businesswire)
29.02.24	Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
27.02.24	Janux Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
26.02.24	Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors (Businesswire)
20.02.24	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 (Businesswire)
08.01.24	Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer (Businesswire)
07.11.23	Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (Businesswire)
08.08.23	Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (Businesswire)
17.07.23	Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Businesswire)
17.07.23	Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs (Businesswire)
09.05.23	Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (Businesswire)
24.04.23	Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences (Businesswire)
20.04.23	Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors (Businesswire)
10.03.23	Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Businesswire)
27.12.22	Janux Therapeutics Submits IND Application For JANX008, EGFR-TRACTr For Solid Tumors (RTTNews)
27.12.22	Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors (Businesswire)
22.11.22	Janux Therapeutics to Present at Upcoming Investor Conferences in November (Businesswire)
10.11.22	Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (Businesswire)
12.10.22	Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer (Businesswire)
23.09.22	Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources (Businesswire)
31.08.22	Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September (Businesswire)
09.08.22	Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (Businesswire)
02.06.22	Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference (Businesswire)
31.05.22	Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer (Businesswire)
10.05.22	Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (Businesswire)
26.04.22	Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr (Businesswire)
21.03.22	JANX Advances Pipeline, INKT To File IND, Will LEGN's Carvykti Hit Blockbuster Status? (RTTNews)
18.03.22	Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
01.03.22	Janux Therapeutics to Present at Upcoming March Investor Conferences (Businesswire)
01.03.22	Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer (Businesswire)
05.01.22	Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference (Businesswire)
15.06.21	Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.98	2.28 %	K V
CieFinRichemont	122.75	1.32 %	K V
Lonza Grp	531.20	0.87 %	K V
Logitech Intl	72.70	0.69 %	K V
Novartis	92.24	0.34 %	K V
Sika	229.70	-0.65 %	K V
Swisscom	505.50	-0.69 %	K V
ABB	49.51	-0.90 %	K V
Holcim	88.82	-1.07 %	K V
UBS Group	27.74	-2.15 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Janux Therapeutics Inc Registered Shs

Aktien Top/Flop

Janux Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten